Objective The laboratory data and clinical features of 90 patients with fever with thrombocytopenia syndrome (SFTS) were analyzed to find out the warning indicators of severe patients and provide basis for timely intervention. Method From March 2020 to September 2021, 90 patients with SFTS were collected from the Infection Department of Anqing Municipal Hospital. They were divided into mild group and severe group according to the severity of the disease, including 44 cases of mild group and 46 cases of severe group. The epidemiological characteristics, clinical characteristics and laboratory indicators of the two groups were compared. Result All 90 cases were sporadic cases, with 88 being farmers, 62 females, and 28 males. The peak of incidence was mainly from April to September. Compared with the mild group, the median age of the severe group was higher (66 years and 62 years, respectively, Z=-2.032, P=0.042); The severe group had a longer heat course (Z=-2.558, P=0.010) and skin ecchymosis and ecchymosis has a higher incidence rate(χ2=9.406, P=0.002); The indexes of calcitonin, creactive protein, creatinine, blood urea nitrogen, aspartate aminotransferase, lactate dehydrogenase, and C reatine kinase in the severe group were higher than those in the mild group (Z values were -2.041, -2.054, -3.576, -4.571, -4.452, -4.993, and -4.500, respectively, P<0.05), while blood calcium (t=-3.471), platelet (Z=-8.124), and lymphocyte count (Z=-1.959) were lower than those in the mild group, with statistical significance (all P<0.05); The incidence rates of central nervous system abnormalities, pneumonia, myocardial damage, bradycardia, liver insufficiency and rhabdomyolysis in the severe group were higher than those in the mild group (χ2=4.155, 8.897, 12.018, 9.961, 16.365, 6.123, all P<0.05). Logistic regression analysis showed that central nervous system abnormalities (OR=20.314, 95%CI:0.886-45.695), PLT(OR=0.93, 95%CI:0.888-0.973), and myocardial damage (OR=4.813, 95%CI:1.149-20.162) are independent risk factors for severe warning. Conclusion The clinical symptoms of SFTS are diverse. If there is a significant decrease in platelets, abnormalities in the central nervous system, or abnormalities in the myocardial enzyme spectrum, patients should be vigilant that they may progress to severe SFTS.